Bioverativ agreed to acquire clinical-stage rare disease biotech True North Therapeutics for $400M upfront cash plus up to $425M in development, regulatory and sales milestones (~$825M total). The lead asset BIVV009 (later sutimlimab) is a first-in-class anti-C1s antibody for cold agglutinin disease. Closed June 2017.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedMay 23, 2017
ClosedJun 28, 2017
Deal value$825M
Deal typeAcquisition/Merger
Therapeutic areaCold agglutinin disease (CAgD); other complement-mediated disorders
IndicationsCold agglutinin disease (CAgD); other complement-mediated disorders